A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder. Here ...
New research has found that certain types of medication used to treat diabetes may be effective in reducing alcohol use. The study looked at whether a type of diabetes medication, called GLP-1 ...
New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat diabetes may be effective in reducing alcohol use.
GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...
GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).
New research, led by experts at the University of Nottingham, has found that certain types of medication used to treat ...
GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...
The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...
Compounded GLP-1s for Weight Loss: What Are They and Are They Safe? GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...
Since the FDA approval of Novo Nordisk’s Wegovy as a treatment for chronic weight management in 2021, followed by the approval of Ozempic the next year, demand for GLP-1 agonist drugs has rapidly ...
HT-6184, a first-in-class, selective, and orally bioavailable inhibitor of the NEK7/NLRP3 inflammasome, is undergoing preclinical evaluation in combination with the GLP-1 agonist semaglutide.